Advertisement
News
Advertisement

Dave Anderson and William Thomsen Join SRI International's Center for Advanced Drug Research to Lead Programs in Proteomics and Metabolic Disease Drug Discovery

Wed, 02/23/2011 - 9:34am
Bio-Medicine.Org

MENLO PARK, Calif., Feb. 23, 2011 /PRNewswire/ -- SRI International, an independent nonprofit research and development organization, announced today that two new principal scientists, Dave Anderson, Ph.D., and William Thomsen, Ph.D., have joined its Center for Advanced Drug Research (CADRE) in Shenandoah Valley, Virginia.

Dr. Anderson will serve as principal scientist in CADRE's proteomics group. He has more than 20 years of experience applying mass spectrometry and proteomics methods to a variety of scientific problems. At SRI, he will apply those methods to set up biomarker analytics for specific disease areas and study host-pathogen interactions and pathogen drug resistance mechanisms.

Prior to joining SRI, Dr. Anderson was senior director of proteomics at Catalyst Biosciences and research fellow for proteomics and target discovery at Rigel Pharmaceuticals. Earlier, he headed the protein chemistry department at Khepri Pharmaceuticals and then at Arris Pharmaceutical following its acquisition of Khepri. In between his positions in the biotech industry, he was a research professor at the University of Oregon.

Dr. Anderson received his Ph.D. from the University of Oregon. He has authored more than 60 publications and holds 42 U.S. patents.

Dr. Thomsen will serve as principal scientist in CADRE's metabolic diseases group, where he will lead research pertaining to metabolic diseases.

He joins SRI with more than 25 years of experience in pharmaceutical drug discovery, with an emphasis on target validation, assay development, high throughput screening, and molecular pharmacology. He has experience with several classes of discovery targets, including G protein coupled receptors, within multiple therapeutic areas, including: disorders of the central nervous system; endocrine, metabolic, cardiovascular, and immunological diseases; and cancer. Most recently, he served as the director of molecular pharmacology at Arena Pharmaceuticals.

'/>"/>

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading